Targeted treatment of bladder cancer, BioClin B round of financing $ 30 million
Release date: 2017-03-27
Yesterday (March 23), BioClin Therapeutics announced the completion of a $30 million Series B financing. This round of investment was led by new investors Sofinnova Ventures and Ysios Capital, as well as existing investors HealthCap, Life Sciences Partners (LSP) and Tekla Capital Management. Since the company's inception, BioClin has raised a total of $59 million.
BioClin Therapeutics is a clinical stage drug company. The company's leading drug candidate is B-701, a potential first-in-class human monoclonal antibody that targets FGFR3 (fibroblast growth factor receptor 3). Currently, the company is evaluating the efficacy of B-701 in the treatment of metastatic bladder cancer.
The proceeds from this round of financing will be used to promote the clinical development of the company's B-701, especially for the treatment of patients with metastatic bladder cancer or metastatic urothelial carcinoma (mUC), who are relapsed or refractory to platinum drugs. Sex.
BioClin's products are in the research line (Source: BioClin's official website)
Stephen Lau, CEO of BioClin Therapeutics, said: "This financing enabled us to expand our 1b/2 trial using B-701 in combination with docetaxel and initiated an assessment of B-701 in combination with atezolizumab Phase 1b/2 trial of anti-drug." Phase 1b/2 study of B-701 in combination with docetaxel will recruit a cohort of patients with FGFR3 mutation or fusion; patients will be given B-701 plus docetaxel or B-701 alone Monotherapy. The second study will evaluate the combination of B-701 and atezolizumab in patients with mUC, including patients overexpressing FGFR3 and FGFR3 mutations or fusion tumors.
In conjunction with financing, Dr. Cory Freedland from Sofinnova Ventures and Dr. Jo?l Jean-Mairet from Ysios Capital will join the board.
Dr. Jol Jean-Mairet said: "In the past few years, there has been significant scientific advancement and understanding of FGFR3 biology and bladder cancer, especially FGFR3 itself as a possible driver of metastatic bladder cancer, and its role in tumor inflammation. The potential role. We are very keen on the clinical plan of B-701 and its potential to enhance the efficacy of immunological checkpoint inhibitors."
Source: Chuangjianhui (WeChat Inno_Insight)
We supply various kinds of peptide including peptide from plants and from animals. Peptide is a kind of Nutritional supplemet for people. Different protein peptides are rich in different nutrients. People can choose suitable protein peptides according to their own body needs. As a kind of nutritionally safe health food, protein peptide plays an important role in improving people's health.
Antioxidation,Regulation of immune function,Contribute to skin care,Delay skin aging and make it whiten,Inhibit the growth of tumor,Hypoglycemic and hypolipidemic,Reduce blood pressure,Inhibit cancer cells,Assisting in decreasing blood glucose,Reduce blood fat, inhibit cholesterol etc.
Quinoa peptide,Ginseng Oligopeptide,Walnut peptide,Wheat protein peptide
Allied Extracts Solutions , https://www.alliedadditives.com